Lipo-Immuno Tech

Executive Summary

Lipo-Immuno Tech is a private biotechnology company headquartered in Cambridge, MA, leveraging a proprietary lipid nanoparticle (LNP) platform to develop next-generation immunotherapies for cancer and infectious diseases. Founded in 2020, the company focuses on delivering nucleic acid payloads that modulate the immune system, aiming to overcome key challenges in drug delivery and enhance therapeutic efficacy. By combining expertise in LNP engineering and immunology, Lipo-Immuno Tech targets both intracellular and extracellular immune checkpoints, potentially enabling more durable and safer responses than traditional approaches. The platform's modularity allows rapid iteration across multiple indications, positioning the company as a versatile player in the rapidly evolving LNP therapeutics space. Although still in preclinical stages, the company's strong scientific foundation and location in a major biotech hub provide a solid base for future growth.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Oncology Candidate40% success
• Q2 2026Series A Financing Round70% success
• Q1 2026Presentation of Preclinical Proof-of-Concept Data85% success